Viridian Therapeutics, Inc.\DE
Extracted from this filing and checked against the source text.
Viridian Therapeutics, Inc.\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions Broker Non-Votes 92,866,008 512,582 193,660 —View on SEC.gov
Viridian Therapeutics, Inc.\DE shareholders approved Election of two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-02 meeting.
1. Election of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 72,363,500 14,475,646 6,733,104 Jennifer K. Moses 86,378,842 460,304 6,733,104View on SEC.gov
Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers at the 2026-06-02 meeting.
4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers: 1 Year 2 Years 3 Years Abstain 86,084,347 29,762 517,682 207,355View on SEC.gov
Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.
3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 83,512,086 3,113,724 213,336 6,733,104View on SEC.gov
1585 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.